Business Context and Reporting Period
This Form 8-K Current Report was filed by Spero Therapeutics, Inc. on October 27, 2021, covering events occurring on October 28, 2021. The Company is a biopharmaceutical firm focused on developing novel antibiotics.
Key Financial Metrics
This filing is a current report regarding a regulatory milestone and does not contain financial statements. Consequently, data regarding revenue, profit, cash flow, margins, debt, and liquidity are not provided in this document.
Material Changes
The primary material event reported is the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for tebipenem HBr (tebipenem pivoxil hydrobromide) tablets. The application seeks approval for the treatment of complicated urinary tract infections, including pyelonephritis, caused by susceptible microorganisms.
Outlook, Risks, and Management Commentary
- Regulatory Timeline: Based on standard FDA review timelines, the FDA has a 60-day period to determine whether the NDA is complete and acceptable for review.
- Disclosure Status: The press release associated with this filing is furnished as Exhibit 99.1 and is not deemed "filed" for purposes of Section 18 of the Exchange Act, nor will it be incorporated by reference into other SEC filings.
Investor Verification Checklist
- Confirm the FDA's determination on the completeness of the NDA within the 60-day review window.
- Review the full text of the press release (Exhibit 99.1) for specific details on the clinical data supporting the NDA.
- Monitor subsequent filings for updates on the FDA review status or potential requests for additional information.